Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cytokinetics, Inc. (NASDAQ: CYTK).

Full DD Report for CYTK

You must become a subscriber to view this report.


Recent News from (NASDAQ: CYTK)

Cytokinetics and Cure SMA Renew and Expand Partnership to Advance Education and Awareness of SMA
ELK GROVE VILLAGE, Ill. and SOUTH SAN FRANCISCO, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Cure SMA and Cytokinetics today announced an expanded partnership to increase education, awareness and fundraising for spinal muscular atrophy (SMA).  As a National Platinum Partner for 2018, Cyto...
Source: GlobeNewswire
Date: May, 17 2018 07:30
How To Play 'Am I Diversified?' In The Pharma/Biotech Space
Background Many investors (including myself) regularly watch or listen to the show "Mad Money" by Jim Cramer on CNBC. As with any celebrity, Mr. Cramer tends to be polarizing, with some loving him and some reveling in pointing out when he is wrong. Rather than focusing on his individual stoc...
Source: SeekingAlpha
Date: May, 03 2018 00:54
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif. and WASHINGTON, May 01, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is renewing its Gold Level Sponsorship of the National W...
Source: GlobeNewswire
Date: May, 01 2018 07:30
Blog Exposure - Zealand's End-of-Phase-2 Meeting with FDA Confirmed the Path Forward for Phase-3 Program of Glepaglutide for Short Bowel Syndrome
Stock Monitor: Cytokinetics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 30, 2018 / Active-Investors.com has just released a free research report on Zealand Pharma A/S (NASDAQ: ZEAL ) ("Zealand"). If you want access to this report all you need to do is sign up now by click...
Source: ACCESSWIRE IA
Date: April, 30 2018 07:30
Cytokinetics' (CYTK) CEO Robert Blum on Q1 2018 Results - Earnings Call Transcript
Cytokinetics, Inc. (CYTK) Q1 2018 Earnings Conference Call April 26, 2018, 16:30 ET Executives Diane Weiser - VP, IR & Corporate Communications Robert Blum - CEO, President & Director Fady Malik - EVP, Research & Development Andrew Wolff - SVP & Chief Medical Of...
Source: SeekingAlpha
Date: April, 26 2018 23:09
Cytokinetics misses by $0.05, misses on revenue
Cytokinetics (NASDAQ: CYTK ): Q1 EPS of -$0.56 misses by $0.05 . Revenue of $5.3M (+27.7% Y/Y) misses by $1.28M . Press Release More news on: Cytokinetics, Incorporated, Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: April, 26 2018 16:10
Cytokinetics, Inc. Reports First Quarter 2018 Financial Results
Completed Enrollment in Phase 2 Study of Reldesemtiv in Patients with SMA; Data Expected in Q2 2018 Preparing to Initiate Second Phase 3 Clinical Trial of Omecamtiv Mecarbil SOUTH SAN FRANCISCO, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) r...
Source: GlobeNewswire
Date: April, 26 2018 16:00
Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference
SOUTH SAN FRANCISCO, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented by John Day, M.D., Ph.D., Professor of Neurolo...
Source: GlobeNewswire
Date: April, 24 2018 07:30
New Research Coverage Highlights MPLX LP, TESARO, LKQ, Cytokinetics, Keysight Technologies, and Charles River Laboratories International - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MPLX LP (NYSE:MPLX), TESARO, Inc. (NASDAQ:TSRO), LKQ Corporation (NASDAQ...
Source: GlobeNewswire
Date: April, 20 2018 08:00
Cytokinetics to Announce First Quarter Results on April 26, 2018
SOUTH SAN FRANCISCO, Calif., April 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report first quarter results on April 26, 2018 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will ho...
Source: GlobeNewswire
Date: April, 12 2018 16:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-177.057.207.306.95259,136
2018-08-167.107.107.206.90225,985
2018-08-157.057.057.156.90203,218
2018-08-146.907.057.0756.85133,464
2018-08-137.006.907.0256.80230,378

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1724,90129,72083.7853Short
2018-08-1620,10576,24026.3707Cover
2018-08-1520,94685,77724.4191Cover
2018-08-1415,06632,84445.8714Short
2018-08-1319,06038,54049.4551Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CYTK.


About Cytokinetics, Inc. (NASDAQ: CYTK)

Logo for Cytokinetics, Inc. (NASDAQ: CYTK)

Not available

 

Contact Information

 

 

Current Management

  • James H. Sabry / President, CEO

Current Share Structure

  • Market Cap: $499,575,045 - 05/15/2018
  • Issue and Outstanding: 54,008,113 - 02/23/2018

 


Recent Filings from (NASDAQ: CYTK)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 02 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 29 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 26 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 15 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: CYTK)

Daily Technical Chart for (NASDAQ: CYTK)


Stay tuned for daily updates and more on (NASDAQ: CYTK)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CYTK)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CYTK is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CYTK and does not buy, sell, or trade any shares of CYTK. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/